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Abstract
Genome-wide association studies (GWAS) of kidney function have uncovered hundreds of loci, primarily in populations of
European ancestry. We have undertaken the first continental African GWAS of estimated glomerular filtration rate (eGFR), a
measure of kidney function used to define chronic kidney disease (CKD). We conducted GWAS of eGFR in 3288 East Africans
from the Uganda General Population Cohort (GPC) and replicated in 8224 African Americans from the Women’s Health
Initiative. Loci attaining genome-wide significant evidence for association (P< 5×10−8) were followed up with Bayesian
fine-mapping to localize potential causal variants. The predictive power of a genetic risk score (GRS) constructed from
previously reported trans-ancestry eGFR lead single nucleotide polymorphism (SNPs) was evaluated in the Uganda GPC. We
identified and validated two eGFR loci. At the glycine amidinotransferase (GATM) locus, the association signal (lead SNP
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haemoglobin beta (HBB) locus, the association signal (lead SNP rs141845179, P=3.0×10−8) has been previously reported. The
lead SNP at the HBB locus accounted for 88% of the posterior probability of causality after fine-mapping, but did not
colocalise with kidney expression quantitative trait loci. The trans-ancestry GRS of eGFR was not significantly predictive
into the Ugandan population. In the first GWAS of eGFR in continental Africa, we validated two previously reported loci at
GATM and HBB. At the GATM locus, the association signal was distinct from that previously reported. These results
demonstrate the value of performing GWAS in continental Africans, providing a rich genomic resource to larger consortia
for further discovery and fine-mapping. The study emphasizes that additional large-scale efforts in Africa are warranted to
gain further insight into the genetic architecture of CKD.
Introduction
Chronic kidney disease (CKD) is a global public health problem,
with adverse outcomes of kidney failure, cardiovascular disease
and premature death. CKD is at least three times more frequent
in Africa, which has limited resources, than in developed coun-
tries (1). With rapidly increasing urbanization, trends towards
unhealthy diets, obesity and increases in metabolic risk factors,
the projected increase in the prevalence of CKD may be even
greater in Africa compared with developed countries (2). The
interplay of genomic and environmental factors contributes to
this complex heterogeneous disease. However, CKD heritability
is estimated to be as high as 30–75% (3). Genetic variants asso-
ciated with CKD may be population specific, indeed the associ-
ation of the APOL1 locus with CKD, which has risen to high fre-
quencieswithinWest Africa due to selection pressures related to
protection against Lassa fever, highlights the potential for novel
discovery in African populations (3). Given the fundamental sig-
nificance of Africa to our human origins, there is a strong scien-
tific need to establish large-scale efforts examining the genetic
contribution to disease susceptibility across diverse populations
within Africa (2,5,6). The clear genomic diversity and allelic dif-
ferentiation among various African populations, in addition to
the lower linkage disequilibrium (LD) between genetic variants,
provides an outstanding opportunity to gain new insights into
disease aetiology and genetic fine-mapping that have relevance
for all ancestry groups (9,10). However, despite the value of
conducting such research in Africa, there is no known genome-
wide association study (GWAS) of kidney function in continental
Africa, with published studies of African ancestry individuals
being limited to African Americans (9,10). Whilst African Amer-
icans typically have a large proportion of West African ances-
try, several studies have shown that the genetic architecture
of African Americans is distinct from that of Africans from
continental Africa (7). The African American population reflects
admixture of people of West and Central-West African descent,
adding to the relevance of studying populations from other
regions of Africa.
Here, we conducted the first continental African GWAS of
estimated glomerular filtration rate (eGFR), a measure of kidney
function used to define CKD, including 3288 individuals from the
Uganda General Population Cohort (GPC). Subsequently, associ-
ations were validated through GWAS of eGFR in a large sample
of 8224 African Americans from the Women’s Health Initiative
(WHI). Together, these GWAS comprised a total of 11 512 African
ancestry individuals. We used the Uganda GPC to: (i) identify
loci associated with eGFR; (ii) fine-map loci by taking advantage
of the finer-grained LD structure in African ancestry popula-
tions and (iii) evaluate the predictive power of an eGFR genetic
risk score (GRS) into the Ugandan population that was derived
from lead single nucleotide polymorphism (SNPs) at previously
reported loci from trans-ancestry GWAS meta-analysis (9,10).
Results
Discovery genetic association
The characteristics, quality control and imputation of the 3288
Uganda GPC study participants are shown in the Methods. We
analyzed associations of eGFR for 20 594 556 SNPs that met an
minor allele frequency (MAF) threshold of at least 0.5% in a
merged panel of imputed GWAS and whole-genome sequences.
We tested for association in a linear mixed model implemented
in genome-wide efficient mixed-model association (GEMMA),
which accounted well for population structure and relatedness.
Our association analysis in the Uganda GPC showed no evidence
of residual population structure with a genomic inflation
factor (λ) of 1.01. We identified two loci attaining genome-
wide significance (P<5×10−8) in GPC (Table 1, Fig. 1) mapping
to glycine amidinotransferase (GATM) (lead SNP rs2433603,
MAF=48%, P=1.0× 10−8) (Fig. 2) and haemoglobin beta (HBB)
(lead SNP rs141845179, MAF=8%, P=3.0×10−8) (Fig. 3). Both
loci have been previously reported as associated with eGFR in
European ancestry and trans-ancestry GWAS meta-analyses
(10,11).
To investigate the relationships between the association sig-
nals identified in the Uganda GPC and those reported in other
populations, we performed conditional analyses. The identified
genetic variant at GATM, rs2433603,was distinct from previously
reported associations (rs1145077, rs1153855 and rs1145093) at
this locus (conditional P =4.0×10−7). This genetic variant is
monomorphic in European ancestry populations and rare in East
Asian ancestry populations in the 1000 Genomes Project Phase
3 (12). This variant has MAF of 48% in Uganda GPC, and 44%
and 37%, respectively, in Luhya in Webuye (LWK), Kenya and
Yoruba in Ibadan (YRI), Nigeria in the 1000 Genomes Project
Phase 3 (12). At the HBB locus, after conditioning on the pre-
viously reported SNP (rs334) at this locus, the association with
the lead SNP (rs141845179)was no longer significant (conditional
P = 0.024). This is because the lead SNP (rs141845179) is in strong
LD (r2 =0.95 in Uganda GPC) with the sickle cell SNP (rs334), and
therefore, they reflect the same signal. Of note, the lead SNP
has MAF of 8% in Uganda but is much less frequent in admixed
Africans in the 1000 Genomes Project Phase 3 (1% in African
Americans from Southwest USA and 2% in Afro-Carribeans from
Barbados). The variant (rs334) in HBB has also been previously
associated with other kidney traits, including urinary albumin
to creatinine ratio and CKD in both African Americans and US
Hispanics/Latinos (13,14).
To investigate the association of previously reported eGFR
loci in Uganda, we also conducted a look-up of 308 lead
SNPs from the largest published meta-analysis of eGFR (10)
(Supplementary Material, Table S1). Of these, 281 variants were
also reported in the GPC GWAS. We observed an enrichment of
SNPs with nominal evidence of association (P < 0.05) in GPC
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Table 1. Loci attaining genome-wide significant (P< 5×10−8) association with eGFR after meta-analysis of GPC and WHI in up to 11 512
individuals of African ancestry
Uganda WHI Meta-Analysis
Locus Lead SNP Chr BP (b37) EA NEA Beta SE MAF P-value Beta SE P-value MAF P-value N
GATM rs2433603 15 45646 226 T C 0.145 0.025 48% 1.0× 10−8 1.0276 0.3042 7.3×10−4 47% 2.4× 10−9 11512
HBB rs141845179 11 5244 665 G T 0.266 0.048 8% 3.0× 10−8 NA NA NA NA 3.0× 10−8 3288
SNP, single nucleotide polymorphism; Chr, Chromosome; BP, base position; EA, effect allele; NEA, Non-effect allele; SE, standard error; NA, not available.
Figure 1. (A) Manhattan plot of genome-wide associations of eGFR in 3288 Ugandan individuals from the GPC. Each point denotes a variant with MAF> 0.5%, with the
x-axis representing the genomic position and y-axis representing the strength of association (−log10 P-value). The dotted line shows the genome-wide significance
threshold of P< 5× 10−8. (B) Quantile-Quantile plot of genome-wide associations of eGFR: the genome-wide genomic control inflation factor was 1.01.
reported eGFR meta-analysis (22 SNPs observed, 7.0 expected,
binomial test P =3.2×10−6). We also replicated eGFR associ-
ations of important African population specific variants near
APOL1/MYH9 (15) (Supplementary Material, Table S2).
The G2 allele is tagged by the deletion rs71785313, which
is monomorphic in the Uganda GPC. The G1 allele is tagged
by two SNPs: rs73885319 and rs60910145. There was no person
homozygous for the G risk allele for rs60910145 and as such we
could not fit the recessive model for this SNP. For rs73885319,
there were 17 carriers of the homozygous risk genotype, but
there was no evidence of association with eGFR in the Uganda
GPC (P =0.22) (Supplementary Material, Table S3). This lack of
association could reflect low power given the low sample size.
Replication of eGFR associations in WHI
Lead SNPs showing strong evidence of association (P <5× 10−5)
in Uganda were considered for replication and meta-analysis
in WHI (Supplementary Material, Table S4). We replicated the
association signal at the lead SNP at the GATM locus in WHI
(P =0.00073, meta-analysis P =2.4×10−9). The lead SNP at
the HBB locus was not available in WHI, and it is rare or
monomorphic in other populations. However, as described
above, rs334 is a close proxy for the lead SNP at the HBB locus
and represents the same eGFR signal. This SNP was available
in WHI, where the association was replicated (P =0.017, meta-
analysis P =1.2× 10−6). No other proxies for the lead SNP at the
HBB locus (r2 >0.9 in the Uganda GPC) were associated with
eGFR in WHI (Supplementary Material, Table S5). No other loci
attained genome-wide significant evidence of eGFR association
after meta-analysis of the Uganda GPC and WHI.
Fine-mapping of loci attaining
genome-wide significance
Bayesian fine-mapping of the GATM and HBB loci was under-
taken in the regionmapping 500 kb up- and down-streamof each
lead SNP, on the basis of association summary statistics from the
meta-analysis of GPC andWHI. At the GATM locus, the 99% cred-
ible set consisted of 63 variants, and no variant accounted for
>50% of the posterior probability (the lead SNP, rs1145092 had a
posterior probability of 13%) (Supplementary Material, Table S6).
At the HBB locus, the 99% credible set consisted of 73 variants,
but with the lead SNP, rs141845179, accounting for 88% of the
posterior probability (Supplementary Material, Table S7).
Colocalization of eGFR association signals
with expression quantitative trait locus (eQTLs)
To gain insight into the causal genes through which eGFR
association signals at the HBB and GATM loci are mediated,
we first considered kidney eQTL in Genotype-Tissue Expression
(GTEx) (16),NephQTL (17), the HumanKidney eQTL Atlas (18) and
RegulomeDB (19). The lead SNPs were not significant eQTLs in
kidney tissue in any of these resources.The lead SNP at theGATM
locus, rs2433603, is a significant eQTL for three genes inmultiple
non-kidney tissues in GTEx (Supplementary Material, Table S8).
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Figure 2. Regional association plot for eGFR in 3288 Ugandan individuals from the GPC at the GATM locus. The lead SNP rs2433603 (15:45646226) (P=1.0×10−8) is
coloured in purple. LD (r2) with other SNPs at the locus was calculated on the basis of the Ugandan SNP genotypes used in this study.
eQTL SNPs, and we cannot therefore conclude that the eGFR
association and eQTLs colocalize. The lead SNP at the HBB locus,
rs141845179, is not a significant eQTL for any gene/tissue in
GTEx. We extended our investigations to other variants in the
99% credible set for each locus and interrogated their regulatory
impact using RegulomeDB (Supplementary Material, Tables S9
and S10). Two variants at the GATM locus (rs2668747 and
rs1153850) have support for regulatory impact from eQTL
data and transcription factor binding. These SNPs showed the
strongest associations with expression of SPATA5L1 in cultured
fibroblasts and whole blood in GTEx but were not in strong LD
with the lead eQTL SNP (rs1365610; r2 =0.076 with rs2668747;
r2 =0.47 with rs1153850) and thus did not support colocalization
with the eGFR signal.
Transferability of trans-ancestry eGFR GRS into Uganda
We used lead SNPs from trans-ancestry a meta-analysis (9) of
eGFR to evaluate the predictive power of an unweighted GRS
into unrelated individuals in the Uganda population (Table 2).
We were unable to undertake a weighted GRS because differ-
ent transformations of the trait were performed in the trans-
ancestry meta-analysis and in the GPC GWAS. Because the SNP
effects were aligned to the eGFR decreasing allele, we expected
an increased score to be associated with lower eGFR. Whilst the
GRS showed the correct direction of effect, it was not signifi-
cantly associated with eGFR in the Uganda population (P =0.076)
and accounted for only 0.04% of the trait variance after account-
ing for age, sex and principal components to adjust for popula-
tion structure.We also leverage the largest trans-ancestry meta-
analysis of eGFR (10) to assess the predictive power of a weighted
GRS into unrelated individuals in the Uganda population. This
GRS also showed the correct direction of effect though not
significantly associated with eGFR in the Uganda population
(P =0.524) and accounted for only 0.01% of the trait variance after
accounting for age, sex and principal components to adjust for
population structure (Table 3).
Sex-stratified analysis of lead SNPs in Uganda GPC
We performed a stratified analysis by sex in the Uganda samples
to determine if any heterogeneity between male and female in
order to ascertain if this contribute to lack of replication in WHI
dataset being comprised of only women. Our analysis shows no
heterogeneity (Supplementary Material, Table S11).
Discussion
In the first GWAS of eGFR in continental Africa, we validated
previously reported eGFR loci mapping to GATM and HBB. The
association in Ugandans at the GATM locus is driven by an
African-specific variant (MAF of 48% in Uganda GPC) and distinct
from those previously reported SNP in European ancestry and
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Figure 3. Regional association plot for eGFR in 3288 Ugandan individuals from the GPC at the HBB locus. The lead SNP rs141845179 (11:5244665) (P=3.0×10−8) is
coloured in purple. LD (r2) with other SNPs at the locus was calculated on the basis of the Ugandan SNP genotypes used in this study.
Table 2. Regression coefficients for the association of the GRS with eGFR in the Ugandan population
Variable Model without GRS Full model
Beta (SE) P R2 Beta (SE) P R2
Age −0.92 (0.01) 2.0× 10−16 0.5492 0.93 (0.015) 2.0×10−16 0.5496
Sex −2.53 (0.56) 7.9× 10−6 −2.55 (0.53) 6.8×10−6
PC1 22.62 (21.53) 0.294 21.77 (21.53) 0.312
PC2 −40.46 (22.01) 0.066 −41.78 (22.01) 0.058
PC3 32.57 (20.17) 0.106 33.18 (20.16) 0.099
PC4 24.34 (23.62) 0.303 24.62 (23.61) 0.297
PC5 −2.95 (21.05) 0.889 −3.40 (21.04) 0.872
GRS −0.17 (0.09) 0.076
in strong LD with the previously reported sickle cell missense
variant rs334 (11) and represented the same underlying eGFR
signal. GATM encodes a mitochondrial enzyme that belongs
to the amidinotransferase family. This enzyme is involved
in creatinine biosynthesis, whereby it catalyzes the transfer
of a guanido group from L-arginine to glycine, resulting in
guanidinoacetic acid, the immediate precursor of creatinine.
The HBB gene provides instructions for making a protein called
beta-globin. Beta globin protein changes related to rs334 causes
sickle cell anaemia. Absence of beta chain causes beta-zero-
thalassemia, and reduced amounts of detectable beta globin
cause beta-plus-thalassemia.
Bayesian fine-mapping revealed that the lead SNP,
rs141845179, accounted for 88% of the posterior probability
of driving the association signal at the HBB locus. At the
GATM locus, the association signal was less precisely refined,
with the lead SNP, rs2433603, accounting for just 13% of the
posterior probability. Unfortunately, the lead SNPs were not
significant eQTLs in kidney tissue in publicly available kidney
gene expression resources. The lack of colocalization could
reflect the fact that these variants are rare in European ancestry
populations and are thus not well represented in the European-
centric eQTL resources used in this investigation, reemphasizing
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Table 3. Regression coefficients for the association of weighted GRS derived from Wuttke et al. (10) with eGFR in the Ugandan population
Variable Model without GRS Full model
Beta (SE) P R2 Beta (SE) P R2
Age −0.92 (0.01) 2.0×10−16 0.5513 −0.92 (0.01) 2.0× 10−16 0.5512
Sex −2.45 (0.56) 1.49×10−5 −2.44 (0.56) 1.53×10−5
PC1 42.86 (14.81) 0.294 42.88 (14.81) 0.003
PC2 −11.08 (14.82) 0.454 −10.60 (14.84) 0.475
PC3 42.23 (14.80) 0.004 42.42 (14.81) 0.004
PC4 −9.59 (14.81) 0.517 −10.17 (14..83) 0.492
PC5 29.97 (14.82) 0.043 30.02 (14.82) 0.043
GRS −12.38 (19.43) 0.524
such as coloc (36) compare patterns of association between
the trait and expression and therefore depend on LD. We were
concerned that the differences on LD structure between the
populations contributing to Uganda GPC (African ancestry) and
the expression resources (European ancestry) would invalidate
the colocalization. GATM protein is a renal proximal tubular
enzyme involved in the creatinine biosynthetic pathway, and
recent studies have shown that fully penetrant heterozygous
mutations in the GATM gene lead to intra-mitochondrial
fibrillary deposition and clinical manifestations of Fanconi
syndrome and CKD (20,21). It is possible that the signal at
the GATM locus reflects associations with the biomarker used
to estimate kidney function (serum creatinine), but genetic
studies in populations are not suited to address this. Many
serum creatinine-based eGFR loci have not been associated
with CKD at genome-wide significance. Whilst this may reflect
lower power to detect association with the disease outcome, a
subset of these loci may represent true genetic influences on
physiologic variation of eGFR but not CKD risk. The GRS derived
from previously reported trans-ancestry lead SNPs (11) for eGFR
was significantly predictive of eGFR in the Ugandan population.
These results show that there is a shared genetic contribution to
eGFR at established loci in continental Africans compared with
African Americans.
The GRS derived from previously reported trans-ancestry
lead SNPs for eGFR was not significantly predictive in the Ugan-
danpopulation.This ismostly likely due to a lack of power inGPC
because of small sample size. However, the lack of transferability
could also be because the way eGFR is calculated in continental
Africa. Studies have shown that there is potential error mea-
surement of serum creatinine in continental Africa that might
lead to inaccurate estimates of kidney disease at individual and
population level (22). To address this issue, a LaboratoryWorking
Group of the National Kidney Disease Education Programme
published recommendations in 2006 to standardize how the
creatinine is measured (22). In this study, eGFR was calculated
using the CKD-Epi formula, without use of the coefficient for
African Americans (22,23). The absence of a validated estimating
equation for kidney function in Africans could be a contributing
factor to the lack of GRS transferability. Another potential expla-
nation for why the GRS was not significant is because the lead
SNPs from the trans-ancestry analysis might not themselves
be causal variants and are not in LD with the causal variant
in the Ugandan population because of differences in LD struc-
ture between ancestry groups. The trans-ethnic meta-analyses
include only variants that are common across populations and
therefore disfavour some important population-specific variants
such as APOL1 and HBB variants.
We attempted to replicate signals from the largest previous
GWAS meta-analysis of eGFR, which included individuals pre-
dominantly of mostly European ancestry (10). After correction
for multiple testing, none of the previously reported lead SNPs
from that study showed significant evidence of association with
eGFR in the Uganda GPC. There are several reasons why this
could occur. First, the previously reported lead SNP might not be
causal and is a poor tag for the causal variant in the Ugandan
population. Second, the causal variant could be very rare or
monomorphic in the Ugandan population, and therefore, an
association would not be detected. Third, the African Ameri-
cans used in the replication set are predominantly West African
ancestry individuals, which might have limited replication of
the Uganda GPC of East African ancestry. Finally, because the
effect sizes are small, there will be limited power to detect
association with the sample size available in the Uganda GPC.
However, we note that there was an enrichment of signals with
the same direction of effect from the largest published meta-
analysis of eGFR (10) and theUgandaGPC,which suggests shared
underlying causal variants that could be identified with larger
sample sizes and/or by testing a better tag for the causal variant
in the Ugandan population.
Despite the relatively high burden of CKD in Africa (29), there
have been no previous GWAS of eGFR in continental Africa. One
limitation of this first GWAS is that, with a small sample size,
we are underpowered to reliably detect associations at genome-
wide significance thresholds. We have applied the traditional
threshold of genome-wide significance (p<5x10−8), which was
originally defined on the basis of LD structure in European
ancestry populations. A more stringent threshold of P<5×10−9
has been proposed in African ancestry populations, to account
for shorter range LD than in those of European ancestry (8). After
meta-analysis, the novel association signal at the GATM locus
attains this stringent threshold. Whilst the association signal at
HBB does not, it has been reported in previous in GWAS (11), and
thus can be considered confirmation of previous results in a new
population, rather than novel discovery.
Our findings further highlight the importance of diverse
ancestries for uncovering novel associations. Larger continental
African meta-analyses are warranted to gain further insight on
the genetic architecture of eGFR. In addition, althoughGWAS still
remains a leading tool to identify loci contributing to complex
diseases, to follow up significant findings and gain biological
insights, the multi-omics resources that would inform these
analyses need to be better represented in Africans. The study
of populations in Africa provides a research framework to help
characterize ethnic-specific patterns of variation in CKD among
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also help identify population-specific genetic or environmental
factors thatmay statistically interact with identified genetic loci.
Given these scientific opportunities, the ascertainment and col-
lation of genetic epidemiological resources with the statistical
resolution to examine these associations in African populations
is a high priority.
Materials and Methods
GPC study participants
The recruited African individuals were part of the nine ethno-
linguistic groups from the Uganda GPC. GPC is a population-
based cohort of roughly 22 000 inhabitants around 25 neighbour-
ing villages of Kyamulibwa, which is a subcounty of Kalungu
district in the countryside in the south-west of Uganda. The
cohort study was founded in the late 1980s by the Medical
Research Council (MRC) UK in partnershipwith theUgandaVirus
Research Institute (UVRI) to primarily investigate the trends in
incidence and prevalence of HIV infection in Uganda. Samples
were collected from research participants during a survey from
the research study area. The study area is clustered into villages
defined by governmental borders ranging in size from 300 to
1500 dwellers and includes numerous families who are resident
within households (26). The GPC Round 22 study took place
in 2011 through collaboration between the University of Cam-
bridge, Wellcome Sanger Institute and MRC/UVRI in Uganda.
This study was approved by the Science and Ethics Committee
of the UVRI, the Ugandan National Council for Science and Tech-
nology and the East of England-Cambridge South NHS Research
Ethics Committee United Kingdom. The study was contained
within one annual survey round of the longitudinal cohort. The
focus of the GPC Round 22 study was to investigate the genetics
and epidemiology of communicable and non-communicable dis-
eases to provide aetiological insights into the genetic variation
in communicable and non-communicable diseases.
GPC study design
The data collection of GPC Round 22 study consisted of fivemain
stages, which took place in 2011 over the course of the year:
mobilization (recruitment and consenting), mapping, census,
survey and feedback of results and clinical follow-up.The census
consisted of a family questionnaire and questionnaire for the
individual recruited fromwithin the family.The family question-
naire was completed by the head of family or another responsi-
ble adult or emancipated minor member of the household. The
household census questionnaire focused on sociodemographic
information about the household, such as the quality of the
house, property ownership and employment of workers. The
individual survey questionnaire captured information on mem-
bers of a household including positionwithin household,marital
status, resident status, childbirth and fertility, tribe and religion.
Information on lifestyle and health was obtained using a stan-
dard questionnaire. This included biophysical measurements
and blood samples (26).We genotyped 5000 and sequenced 2000
samples from nine ethno-linguistic groups from the GPC, which
includes related individuals.
GPC genotyping and quality control
Individuals (n=5000) were genotyped on the Illumina
HumanOmni2.5-8 array, and 4872 were retained following a
pre-quality control stage. GWAS genotype data were subjected
to stringent quality control filtering. Of a total of 2 314174
autosomal variants genotyped, 39 368 were excluded because
they did not pass SNP quality thresholds for call rate (<97%,
n=25037 SNPs) and deviation fromHardy–Weinberg equilibrium
(HWE) (P<10−8, n=14331 SNPs) as reported in (8). We excluded
91 individuals who failed to meet the quality control for call rate
(>97%) or had gender mismatch compared with X-chromosome.
We carried out further quality control for the GWAS analysis, for
which three samples were excluded as heterozygosity outliers
(heterozygosity ≥3 SD from mean). Additional six samples were
excluded due to potential contamination.
Curation of GPC sequence data
An additional 2000 Uganda samples (UG2G) underwent low cov-
erage whole-genome sequencing on the Illumina HiSeq 2000
with 75 bp paired end reads, at low coverage, with an average
coverage of 4× for each sample. In total, 1978 of them passed
quality control. The workflow for data processing and descrip-
tion of UG2G has been previously described in more detail (5,6).
Briefly, after the generation of raw reads on Illumina HiSeq
sequencing machine, the reads were converted to BAM format
using Illumina2BAM.We Mapped the Human samples using the
BWA backtrack algorithmwith the GRCh37 1000 Genomes phase
II reference.
GPC haplotype phasing and imputation
into genotype data
Haplotype phasing of GWAS data was carried out using
SHAPEIT2 (27) with standard parameters. A previous study has
shown that phasing with SHAPEIT2 in this cohort with dense
genotype data provides very high accuracy even when pedigree
structure is not explicitly specified during phasing (28).
Imputation of the pre-phased genotype data was carried out
with IMPUTE2 (29) using a merged reference panel of the whole-
genome sequence data from the African Genome Variation
Project (30), the UG2G described earlier and the 1000 Genomes
Project phase 3 (1000 Genomes Project Consortium, 2015) (12)
following standard recommendations. Imputation was carried
out in chunks of 2 MB and then concatenated. Imputed SNPs
were further filtered for info quality >0.3 and an MAF >0.5%.
‘Duplicate variants were removed post imputation.We removed
both duplicates as we did not consider this to be reliable.’
Merging of GPC genotype and sequence data
The final dataset used for this analysis included merged geno-
type data on 4772 and sequence data on 1978 individuals. We
note that there are 343 individuals who have been genotyped
and sequenced; for these individuals, we only included the
sequence data and not the genotype data. The final dataset,
therefore, included 6407 individuals (4429 with genotype and
imputed data and 1978 with sequence data).
Followingmerging,we assessed and removed any systematic
differences between imputed genotype data and sequence data.
We did this by carrying out principal component analysis using
merged data for the 343 individuals who had been genotyped
and sequenced in duplicate to examine whether there was sep-
aration by data mode (imputed genotype data and sequenced
data). Full details were reported in (5). For GWAS analyses, we
only included a subset of variants (n=20594556) that met an
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GPC laboratory test and phenotype definition
Creatinine wasmeasured using the enzymaticmethod traceable
to an isotope dilution mass spectrometry method (IDSM) (31).
Collectively, the serum creatinine level was measured in 3288
Uganda individuals for Round 22 (23). The eGFR was calculated
using the CKD-Epi formula, without use of the coefficient for
African Americans (22). We carried out the inverse rank normal
transformation of eGFR residuals after adjusting for age, age2
and sex.
Statistical methods for association analysis in GPC
GWASwas performedusing the standardmixed-model approach
implemented in GEMMA version 24 (32) for analysis of pooled
data from 3288 individuals (2266 genotyped and 1022 whole
genome sequenced individuals have eGFR measurements) in
GPC and tested association of eGFR, under an additive model,
with 20 594556 SNPs that met an MAF threshold of at least 0.5%
in the merged panel of imputed GWAS and whole-genome
sequences. To maximize discovery, we used the leave one
chromosome out (LOCO) approach for analysis (5,6). In this
approach each chromosome is excluded from generation of the
kinshipmatrix in turn, for association analysis formarkers along
that chromosome. This ensures that causal SNPs at a locus on
a given chromosome are not used for generation of the kinship
matrix used in analysis of that specific chromosome. Therefore,
we generated 22 kinship matrices for analysis, each excluding
the chromosome being analyzed using the given matrix. For
computational efficiency, and to avoid correlation effects due
to LD, we LD pruned the data prior to calculation of the kinship
matrix for each LOCO analysis.
For all loci attaining genome-wide significance that have
been previously reported in GWAS of eGFR, we performed con-
ditional analyses in GEMMA to determine whether the associ-
ation signals were distinct. Specifically, we included genotypes
under an additive model at previously reported lead SNPs as a
fixed effect in the mixed model. We also searched for evidence
of multiple distinct signals of association in GPC by including
genotypes at the lead SNP as a fixed effect in the mixed model.
WHI study design
The WHI is a study of postmenopausal women and health out-
comes, funded by the National Heart Lung and Blood Institute.
A total of 161 808 women aged 50–79 years old were recruited
from 40 clinical centres in the United States between 1993 and
1998. Study protocols and consent forms were approved by the
institutional review boards at all participating institutions. The
WHI SHAReminority cohort includes 8515 self-identifiedAfrican
American women, who provided written informed consent for
study participation and DNA analysis.
WHI genotyping, imputation and phenotype
transformation
African American women who consented to genome-wide
scanning underwent genotyping with the Affymetrix Genome-
WideHumanSNPArray 6.0 containing 906000 SNPs.The samples
underwent initial quality control including removal of samples
with poor DNA quality, abnormal sex chromosomes, relatedness
and low call rates as previously reported (9). Additional quality
control measurements were made at the SNP level assessing
for HWE (goodness-of-fit χ2>10), call rates 90%, monomorphic
SNPs and MAFs 1%. We used frappe to estimate individual
admixture, and estimates were included in models to account
for population stratification.
After quality control, GWAS scaffolds were pre-phased and
imputed using MaCH/minimac r2 ≥0.3, and 13096173 SNVs
passing quality control were tested for association with eGFR.
For each individual, eGFR was calculated from serum creatinine
(mg/dl, IDSM measured assay) using the Modification of Diet in
Renal Disease equation.
Replication and meta-analysis
All lead SNPs (separated by 500 kb) apart showing strong evi-
dence of association (P <5× 10−5) in the Uganda GPC were
considered for replication in WHI. In view of the different scales
of the effect sizes, association summary statistics of Uganda GPC
and WHI were aggregated using the fixed-effects meta-analysis
on the basis of the sample size weighting of Z-scores (Stouffer’s
method) in METAL (33).
Sex-stratified analysis
In order to ascertain if female-only replication cohort might
limit our finding, we stratified the Uganda GPC dataset by sex.
eGFR association testing was performed separately inmales and
females using GEMMAversion 24, and the resultswere combined
scores Stouffer’s method implemented in METAL (33).
Recessive model of APOL1 G1/G2 risk allele
APOL1 G1/G2 alleles have been reported to be strongly associ-
ated with kidney disease in individuals of African ancestry. We
attempted to fit the recessive model for the two APOL1 risk
haplotypes (G1, tagged by rs73885319A>G and rs60910145 T>G;
G2, tagged by rs71785313 TTATAA/−). This was done by recoding
the genotypes of each SNP for carriage of the homozygous
risk genotype. We tested for association with eGFR under this
recessive model via linear regression whilst correcting for age,
sex and principal components as covariates using only unrelated
individuals from the Uganda GPC.
Fine-mapping
To fine-map the GATM and HBB loci, we first conducted meta-
analysis (as described above) of association summary statistics
fromUganda GPC andWHI for all SNPsmappingwithin 500 kb of
the lead SNP at each locus. We used a Bayesian approach (34) to
fine-map the two loci, where the meta-analysis Z-score for the
ith SNP, denoted Zi,was used to compute a Bayes’ factor in favour
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derived by sorting the Bayes’ factors of the SNPs from the high-
est to the lowest, and then included SNPs needed to attain a
cumulative posterior probability that is ≥0.99.
eQTL analysis
We considered publicly available kidney eQTL resources from
the GTEx Project (16), NephQTL (17), the Human Kidney eQTL
Atlas (18) and RegulomeDB (19). We conducted a look up of the
lead SNP at each locus for association with gene expression
in kidney tissue using a range of publicly available resources:
(i) kidney cortex in GTEx; (ii) glomerular and tubulointerstitial
kidney tissue in NephQTL; (iii) whole kidney, glomerulus and
tubules in the HumanKidney eQTLAtlas.As secondary analyses,
we also conducted a look up of the lead SNP at each locus for
association with gene expression in other tissues available in
GTEx. Where the lead SNP was a significant eQTL in a given tis-
sue, we assessed the extent of LD with the lead eQTL SNP in the
Uganda GPC to evaluate the evidence in favour of colocalization.
We also interrogated variants in the 99% credible set for evidence
of regulatory impact using RegulomeDB.
Genetic risk score
After removing 817 first-degree relatives from the Uganda GPC
cohort derived from PIHAT values >0.5, we calculated principal
components using –pca in PLINK (35). Lead SNPs with effects
on trait aligned to the eGFR decreasing allele from a previously
published trans-ancestrymeta-analysis (9) of eGFR (n =120 SNPs)
and (n =246 matching SNPs from (10)) were selected separately
and used to compute an unweighted GRS by counting the num-
ber of eGFR decreasing alleles, using the allelic scoring approach
in PLINK (35). The predictive power of the GRS was evaluated
by assessing the change in R2 (variance explained) when it was
added to the linear model of eGFR adjusted for age, sex and
principal components.
Supplementary Material
Supplementary Material is available at HMG online.
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